# A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

> **NCT04878211** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis (RMS)

## Interventions

- **DRUG:** Ofatumumab
- **BIOLOGICAL:** mRNA COVID-19 vaccine
- **DRUG:** interferon or glatiramer acetate

## Key facts

- **NCT ID:** NCT04878211
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-10
- **Primary completion:** 2023-04-14
- **Final completion:** 2023-04-14
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04878211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04878211, "A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04878211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*